Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology portfolio.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis (AD).

VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque ...

Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. VTAMA cream, 1%, is a novel nonbiologic, non-steroidal topical therapy ...

The recent acquisition of Dermavant, which brought VTAMA into Organon's portfolio, has been viewed as a strategic move to broaden the company's dermatology offerings in the U.S. market.

Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Organon (OGN) announced completion of its acquisition of Dermavant Sciencesfrom Roivant (ROIV). Dermavant is a company dedicated to developing ...

3,4 “The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...

Analysts project VTAMA's sales potential to reach $500 million or more, contingent upon successful pediatric market penetration and patients switching from topical steroids. The recent acquisition of ...